Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interarytenoid Botox + PPI vs PPI for Vocal Fold Granuloma
NCT01678053Phase 2Withdrawn
- Start
- Sep 2012
- Primary completion
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of botulinum toxin type A in Laryngeal granuloma (2 arms). Primary endpoint: Complete resolution of vocal fold granuloma at 3 months. Planned start Sep 2012; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
Laryngeal granuloma
Beyond the preview
Go deeper on NCT01678053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01678053.